Smiling at scale Decision Makers

Clear aligners continue to increase in demand and 3D printing has proven to be an ideal technology to produce these mass-customized devices. Silicon Valley-based Carbon has made clear aligners one of its top priorities for expansion in the European market by offering the most seamless solution to produce them at scale using its L1 production solution optimized for clear aligner models. As a Sales Director for dental aligner solutions in Europe, Lea McGurk, has been tasked with helping dental laboratories across Europe understand the benefits of turning to Carbon’s turnkey, the subscription-based business model for their clear aligner production requirements. In this exclusive interview, we dig a little deeper into how Carbon makes it possible to go from one printer to a fleet of printers.

New Cadillac CELESTIQ features 115 3D printed parts Additive Manufacturing

As anticipated by 3dpbm in July 2022, the Cadillac CELESTIQ, described by GM “as the most technologically advanced Cadillac ever”, features an impressive 115 3D printed parts in the production vehicle, demonstrating GM’s broadest use of this process. Additively manufactured parts include the steering wheel center, which is the largest metal part GM has printed in production, combining the show surface and the structural B-side of the part. Another 3D printed part is the seat belt adjustable guide loop, which is GM’s first safety-related 3D printed part.


Stratasys makes strategic investment in Axial3D Medical

Med-tech startup Axial3D has announced the closing of a $15 million investment round led by a strategic investment of $10 million from Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing solutions. This is Stratasys’ first investment in Axial3D. The two companies also will be providing a joint offering to make patient-specific 3D printing solutions for hospitals and medical device manufacturers more accessible so it becomes a mainstream healthcare solution.


Carbon’s bioabsorbable elastomer shows biocompatibility in vivo Bioprinting

Carbon’s developmental bioabsorbable elastomer platform has demonstrated biocompatibility in vivo, with all samples being designated as non-toxic and exhibiting tunable times for full absorption. This latest milestone indicates the elastomer’s potential future development in biomedical lattice applications such as soft tissue repair, wound dressings, and nerve conduits.